ABRAMS: You are right that we do not want to see trials that a lot of time and effort has been put into, and patients have joined, and then don’t meet their enrollment goals. We have to do more, and we’ve recognized that.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
